Financing the Acquisition of a Medicare-Certified Home Health Agency

From SBA 7(a) loans to seller earnouts, understand the capital structures that work for home health acquisitions in the $1M–$5M revenue range.

Find Home Health Agency Deals SBA Calculator →

Acquiring a home health agency involves unique financing considerations beyond standard business loans. Lenders must underwrite Medicare/Medicaid reimbursement risk, CHOW approval timelines, and payor mix concentration. Buyers typically combine SBA 7(a) debt, seller financing, and equity injection to close deals efficiently while managing regulatory transition risk.

Financing Options for Home Health Agency Acquisitions

SBA 7(a) Loan

$500K–$4MPrime + 2.75%–3.5% (variable)

The most common financing vehicle for home health acquisitions. Lenders underwrite based on historical Medicare billing revenue, EBITDA margins, and payor mix stability. CHOW approval timing must be factored into closing conditions.

Pros

Low buyer equity requirement of 10–15% allows capital preservation for post-close working capital and staffing needs
10-year loan term reduces monthly debt service burden on agencies with 10–20% EBITDA margins
SBA lenders experienced in healthcare can navigate Medicare revenue verification and billing compliance underwriting

Cons

×CHOW process delays of 90–180 days can complicate SBA disbursement timing and require bridge arrangements
×Lenders may discount Medicare AR and reduce loan proceeds if billing compliance history shows claim denial rates above 5–10%
×Personal guarantee required, creating full recourse exposure for individual buyers acquiring government-reimbursed businesses

Seller Financing / Seller Note

$100K–$600K6%–8% fixed, interest-only during CHOW period

Seller carries 10–20% of the purchase price as a subordinated note, often tied to CHOW approval milestones or patient census retention thresholds. Common in home health deals where transition risk is elevated.

Pros

Aligns seller incentives with successful CHOW approval, payor re-enrollment, and staff retention post-close
Reduces SBA loan amount needed, improving debt service coverage ratio and overall deal feasibility
Flexible repayment terms can accommodate seasonal Medicare billing cycles and census fluctuations

Cons

×Sellers may resist subordination to SBA lender, requiring negotiation on intercreditor terms and standby periods
×If patient census drops post-close, seller note payments strain cash flow during a critical transition period
×Earnout structures tied to revenue thresholds create disputes if referral sources shift after seller departure

Equity / Buyer Cash Injection

$150K–$800KN/A (equity)

Buyers typically inject 10–20% equity at close. PE-backed roll-up platforms may use fund capital; individual buyers use personal savings or investor partnerships. Adequate equity protects against Medicare reimbursement timing gaps.

Pros

Meets SBA equity injection requirements and signals financial commitment to healthcare-experienced lenders and sellers
Provides working capital buffer for payroll continuity during CHOW transition when Medicare billing is temporarily disrupted
Reduces leverage, improving DSCR and qualifying for better SBA loan terms from healthcare-focused lenders

Cons

×Higher equity requirement reduces buyer IRR, particularly in roll-up strategies where capital must be deployed across multiple acquisitions
×Individual buyers pulling from personal savings face concentration risk if post-CHOW Medicare reimbursement is delayed beyond 90 days
×PE platforms requiring co-investors may slow deal execution, creating risk of losing deals to faster-moving individual buyers

Sample Capital Stack

$2,000,000 (4x EBITDA on a $500K EBITDA home health agency with active Medicare certification and 75 active patients)

Purchase Price

~$16,800/month SBA payment (10-year term, 9.5% rate) + $2,000/month seller note interest-only during CHOW = ~$18,800 total

Monthly Service

Approximately 1.35x based on $500K EBITDA and $226K annual debt service — above typical 1.25x SBA minimum threshold

DSCR

SBA 7(a) Loan: $1,500,000 (75%) | Seller Note tied to CHOW approval: $300,000 (15%) | Buyer Equity Injection: $200,000 (10%)

Model your own deal structure →

Lender Tips for Home Health Agency Acquisitions

1Work with SBA lenders who have closed healthcare or Medicare-reimbursed business deals — they understand CHOW timing, billing compliance underwriting, and how to structure closings around payor re-enrollment delays.
2Request a third-party billing compliance audit before submitting your SBA loan package — lenders will scrutinize Medicare claim denial rates, RAC audit history, and overpayment exposure as credit risk factors.
3Structure seller note repayment to begin only after successful CHOW approval and CMS provider number transfer — this protects cash flow during the critical 90–180 day post-close transition period.
4Provide lenders with a clean 3-year payor mix breakdown showing Medicare, Medicaid, managed care, and private pay percentages — government revenue concentration above 90% may trigger additional underwriting scrutiny.

Frequently Asked Questions

Can I use an SBA loan to buy a home health agency?

Yes. Home health agencies are SBA 7(a) eligible. Lenders underwrite based on EBITDA, Medicare billing history, and payor mix. CHOW approval timelines must be coordinated with loan disbursement to avoid cash flow disruptions at close.

How does the CHOW process affect acquisition financing?

CMS CHOW approval takes 90–180 days post-close. During this period, Medicare billing under the new provider number is suspended. Buyers need working capital reserves or bridge financing to cover payroll and operating expenses until reimbursements resume.

What DSCR do lenders require for home health agency acquisitions?

Most SBA lenders require a minimum 1.25x DSCR. For home health agencies, lenders may apply a haircut to Medicare revenue projections if billing compliance risks exist, effectively requiring stronger EBITDA margins to qualify.

How is a home health agency valued for financing purposes?

Lenders and buyers typically value agencies at 3.5x–6x EBITDA depending on Medicare star ratings, payor mix, census size, and compliance history. Agencies with strong clinical outcomes and diversified referral sources command premiums near the top of that range.

More Home Health Agency Guides

Buy a Home Health Agency Business →Valuation Guide →SBA Loan Guide →Deal Structure →Common Mistakes →SBA Calculator →Deal Structure Builder →

Ready to finance your Home Health Agency acquisition?

DealFlow OS surfaces acquisition targets and helps you structure the deal. Free to join.

Start finding deals — free

No credit card required